{"id":15796,"date":"2021-04-13T08:34:09","date_gmt":"2021-04-13T08:34:09","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/ie\/?page_id=15796"},"modified":"2023-03-28T06:25:41","modified_gmt":"2023-03-28T06:25:41","slug":"lluis-perez","status":"publish","type":"page","link":"https:\/\/www.neuraxpharm.com\/ie\/about-us\/executive-committee\/lluis-perez","title":{"rendered":"LLU\u00cdS P\u00c9REZ"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

https:\/\/www.linkedin.com\/in\/lluis-perez-796bb934\/<\/a><\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
Neuraxpharm<\/a><\/div>\n\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

LLU\u00cdS P\u00c9REZ<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tLlu\u00eds joined Neuraxpharm as Chief Financial Officer (CFO) in April 2018. His professional background and expertise are focused on the fields of finance and corporate finance control, including extensive international experience within large multinational companies.\n\nFor more than eight years, Llu\u00eds developed his professional career as Group CFO in various business units within the Celsa Group, the second largest steel producer in Europe with bases in the UK, Scandinavia and Poland, and as Group CFO for the private equity-owned Goldcar Group.\n\nHe is an expert in the integration of subsidiaries, co-ordination of multi-site finance departments, refinancing, analysing the feasibility of new investments and leading merger and acquisition processes.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

https:\/\/www.linkedin.com\/in\/lluis-perez-796bb934\/ Neuraxpharm LLU\u00cdS P\u00c9REZ Llu\u00eds joined Neuraxpharm as Chief Financial Officer (CFO) in April 2018. His professional background and expertise are focused on the fields of finance and corporate finance control, including extensive international experience within large multinational companies. For more than eight years, Llu\u00eds developed his professional career as Group CFO in various business […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":1998,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-15796","page","type-page","status-publish","hentry"],"yoast_head":"\nLLU\u00cdS P\u00c9REZ - Neuraxpharm IE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LLU\u00cdS P\u00c9REZ\" \/>\n<meta property=\"og:description\" content=\"https:\/\/www.linkedin.com\/in\/lluis-perez-796bb934\/ Neuraxpharm LLU\u00cdS P\u00c9REZ Llu\u00eds joined Neuraxpharm as Chief Financial Officer (CFO) in April 2018. His professional background and expertise are focused on the fields of finance and corporate finance control, including extensive international experience within large multinational companies. For more than eight years, Llu\u00eds developed his professional career as Group CFO in various business […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm IE\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-28T06:25:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/ie\/wp-content\/uploads\/sites\/21\/2023\/03\/lluis-perez.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.neuraxpharm.com\/ie\/about-us\/executive-committee\/lluis-perez\",\"url\":\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez\",\"name\":\"LLU\u00cdS P\u00c9REZ - Neuraxpharm IE\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/ie\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.neuraxpharm.com\/ie\/wp-content\/uploads\/sites\/21\/2023\/03\/lluis-perez.jpg\",\"datePublished\":\"2021-04-13T08:34:09+00:00\",\"dateModified\":\"2023-03-28T06:25:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#primaryimage\",\"url\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/21\/2023\/03\/28062105\/lluis-perez.jpg\",\"contentUrl\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/21\/2023\/03\/28062105\/lluis-perez.jpg\",\"width\":716,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"About Neuraxpharm\",\"item\":\"https:\/\/www.neuraxpharm.com\/ie\/about-us\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Executive Committee\",\"item\":\"https:\/\/www.neuraxpharm.com\/ie\/about-us\/executive-committee\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"LLU\u00cdS P\u00c9REZ\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.neuraxpharm.com\/ie\/#website\",\"url\":\"https:\/\/www.neuraxpharm.com\/ie\/\",\"name\":\"Neuraxpharm IE\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.neuraxpharm.com\/ie\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LLU\u00cdS P\u00c9REZ - Neuraxpharm IE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez","og_locale":"en_US","og_type":"article","og_title":"LLU\u00cdS P\u00c9REZ","og_description":"https:\/\/www.linkedin.com\/in\/lluis-perez-796bb934\/ Neuraxpharm LLU\u00cdS P\u00c9REZ Llu\u00eds joined Neuraxpharm as Chief Financial Officer (CFO) in April 2018. His professional background and expertise are focused on the fields of finance and corporate finance control, including extensive international experience within large multinational companies. For more than eight years, Llu\u00eds developed his professional career as Group CFO in various business […]","og_url":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez","og_site_name":"Neuraxpharm IE","article_modified_time":"2023-03-28T06:25:41+00:00","og_image":[{"url":"https:\/\/www.neuraxpharm.com\/ie\/wp-content\/uploads\/sites\/21\/2023\/03\/lluis-perez.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/ie\/about-us\/executive-committee\/lluis-perez","url":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez","name":"LLU\u00cdS P\u00c9REZ - Neuraxpharm IE","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/ie\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#primaryimage"},"thumbnailUrl":"https:\/\/www.neuraxpharm.com\/ie\/wp-content\/uploads\/sites\/21\/2023\/03\/lluis-perez.jpg","datePublished":"2021-04-13T08:34:09+00:00","dateModified":"2023-03-28T06:25:41+00:00","breadcrumb":{"@id":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#primaryimage","url":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/21\/2023\/03\/28062105\/lluis-perez.jpg","contentUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/21\/2023\/03\/28062105\/lluis-perez.jpg","width":716,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuraxpharm.com\/about-us\/executive-committee\/lluis-perez#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"About Neuraxpharm","item":"https:\/\/www.neuraxpharm.com\/ie\/about-us"},{"@type":"ListItem","position":2,"name":"Executive Committee","item":"https:\/\/www.neuraxpharm.com\/ie\/about-us\/executive-committee"},{"@type":"ListItem","position":3,"name":"LLU\u00cdS P\u00c9REZ"}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/ie\/#website","url":"https:\/\/www.neuraxpharm.com\/ie\/","name":"Neuraxpharm IE","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/ie\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/pages\/15796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/comments?post=15796"}],"version-history":[{"count":24,"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/pages\/15796\/revisions"}],"predecessor-version":[{"id":18249,"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/pages\/15796\/revisions\/18249"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/pages\/1998"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/ie\/wp-json\/wp\/v2\/media?parent=15796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}